The county joins municipalities across the country suing Eli Lilly, CVS Caremark, and others for sky-high prices.

Also Read: Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say The collaboration focuses on discovering and developing RNA-editing ...

The view from CVS on this deal, it was to go 1-o-1 ... Lucas, thank you very much, and Mike, thank you. Thank you, Eli Lilly.

In its lawsuit against several healthcare giants, the county contends insulin costs jumped more than 1,000 percent, with medications that cost manufacturers approximately $2 per vial to produce ...

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

Shares in Eli Lilly have weakened after CVS Health, one of the largest pharmacy benefit managers (PBMs) in the US, said it would no longer cover its obesity therapy Zepbound. The shares closed ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said ...

With $27 billion earmarked to expand its U.S. production footprint starting this year, Eli Lilly is busy scouting out ...